Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy

[1] Ahmed SH(2006)Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease Circulation 113 2089-2096

[2] Clark LL(1995)Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments J Biol Chem 270 5872-5876

[3] Pennington WR(2003)Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats Pharmacol Res 48 429-435

[4] Webb CS(2005)Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E Am J Physiol Heart Circ Physiol 288 H227-H234

[5] Bonnema DD(1995)Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18 708-714

[6] Leonardi AH(2006)Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction Am J Physiol Heart Circ Physiol 292 H1847-H1860

[7] McClure CD(2004)Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase Diabetes 53 463-473

[8] Spinale FG(1998)The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study J Biol Chem 273 871-880

[9] Zile MR(1999)Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy Ann N Y Acad Sci 878 559-562

[10] Aimes RT(1995)Matrix metalloproteinases and cardiovascular disease Circ Res 77 863-868

[1] Ahmed SH(2006)Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease Circulation 113 2089-2096

[2] Clark LL(1995)Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments J Biol Chem 270 5872-5876

[3] Pennington WR(2003)Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats Pharmacol Res 48 429-435

[4] Webb CS(2005)Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E Am J Physiol Heart Circ Physiol 288 H227-H234

[5] Bonnema DD(1995)Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18 708-714

[6] Leonardi AH(2006)Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction Am J Physiol Heart Circ Physiol 292 H1847-H1860

[7] McClure CD(2004)Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase Diabetes 53 463-473

[8] Spinale FG(1998)The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study J Biol Chem 273 871-880

[9] Zile MR(1999)Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy Ann N Y Acad Sci 878 559-562

[10] Aimes RT(1995)Matrix metalloproteinases and cardiovascular disease Circ Res 77 863-868